Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugs

Drug Metabolism and Disposition

Volumn 36, Issue 2, 2008, Pages 353-360

  Helsby, Nuala A ^a,b   Goldthorpe, Michael A ^a   Tang, Magdalene H Y ^a   Atwell, Graham J ^b   Smith, Eileen M ^b   Wilson, William R ^b   Tingle, Malcolm D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (DIETHYLAMINO) N (2 HYDROXYETHYL) 3,5 DINITROBENZAMIDE; 2 [[2 BROMOETHYL] 2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANETHIOSULFONATE; 2 [BIS(2 BROMOETHYL)AMINO] N (2 HYDROXYETHYL) 3,5 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BISCHLOROETHYL 2,4 DINITROBENZAMIDE; N (2 HYDROXYETHYL) 3,5 DINITROBENZAMIDE 2 MUSTARD DERIVATIVE; SN 27686; SN 27858; SN 29546; SN 29893; UNCLASSIFIED DRUG;

ACETYLATION; AEROBIC METABOLISM; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEALKYLATION; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; FEMALE; GLUCURONIDES; HUMANS; MALE; MICE; MICE, NUDE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MUSTARD COMPOUNDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

BRASSICACEAE; CANIS FAMILIARIS; RATTUS;

EID: 38749131554     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018739     Document Type: Article

References (26)

1. Anlezark GM, Melton RG, Sherwood RF, Wilson WR, Denny WA, Palmer BD, Knox RJ, Friedlos F, and Williams A (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50:609-618.
2. Atwell GJ, Yang S, Pruijn FB, Pullen SM, Hogg A, Patterson AV, Wilson WR, and Denny WA (2007) Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. J Med Chem 50:1197-1212.
3. Denny WA and Wilson WR (1986) Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 29:879-887.
4. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, and Patterson, A.V (2007). Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for cytochrome P450 reductase under hypoxia. Biochem Pharmacol 74, 810-820.
5. Helsby NA, Ferry DM, Patterson AV, Pullen SM, and Wilson WR (2004) 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 90:1084-1092.
6. Helsby NA, Wheeler SJ, Pruijn FB, Palmer BD, Yang S, Denny WA, and Wilson WR (2003) Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem Res Toxicol 16:469-478.
7. Johansson E, Parkinson GN, Denny WA, and Neidle S (2003) Studies on the nitroreductase prodrug-activating system: crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J Med Chem 46:4009-4020.
8. Kestell P, Pruijn FB, Siim BG, Palmer BD, and Wilson WR (2000) Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumourbearing mice. Cancer Chemother Pharmacol 46:365-374.
9. Khan S, Sood C, and O'Brien PJ (1996) The involvement of cytochrome P4502E1 in 2-bromoethanol-induced hepatocyte cytotoxicity. Pharmacol Toxicol 78:241-248.
10. Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P, and Ching, L.-M (2004) Metabolism of thalidomide in liver microsomes of mice, rabbits and humans. J Pharmacol Exp Ther 310:571-577.
11. Palmer BD, van Zijl P, Denny WA, and Wilson WR (1995) Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino] -2,4-dinitrobenzamide. J Med Chem 38:1229-1241.
12. Palmer BD, Wilson WR, Cliffe S, and Denny WA (1992) Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J Med Chem 35:3214-3222.
13. Palmer BD, Wilson WR, Pullen SM, and Denny WA (1990) Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J Med Chem 33:112-121.
14. Patel, K, Lewiston D, Gu Y, Hicks KO, and Wilson WR (2007) Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-preprodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 856:302-311.
15. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Syddall SP, Hicks KO, Atwell GJ, et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104. Clin Cancer Res 13:3922-3932.
16. Siim BG, Denny WA, and Wilson WR (1997) Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 9:357-369.
17. Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson, WR, Patterson AV (2007). The nitroreductase prodrug SN 28343 enhances the potency of the systemically administered armed oncolytic adenovirus ONYX-411NTR. Cancer Gene Ther 14:953-957.
18. Sood C and O'Brien PJ (1993) Molecular mechanisms of chloroacetaldehyde- induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 46:1621-1626.
19. Springate JE (1997) Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 17:75-79.
20. Tang MHY, Helsby NA, Wilson WR, and Tingle MD (2005) Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology 216:129-139.
21. Tercel M, Wilson WR, and Denny WA (1995) Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. J Med Chem 38:1247-1252.
22. Wen Z, Martin DE, Bullock P, Lee, K-H, and Smith PC (2007) Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos 35:440-448.
23. Wheeler SJ (1999). Reactivity and cytotoxicity of the reduction products of the bioreductive prodrugs SN 23862 and CB 1954. Masters thesis, University of Auckland.
24. Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, and Patterson AV (2007) Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 167:625-636.
25. Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, and Denny WA (2002) Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res 62:1425-1432.
26. Zhou S, Paxton JW, Tingle MD, and Kestell P (2000) Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449 -1456.